{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:20Z","timestamp":1790832440163,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004626.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T00:00:00Z","timestamp":1350432000000}}],"reference-count":129,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004626.pub3","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T16:56:19Z","timestamp":1349974579000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies"],"prefix":"10.1002","volume":"2012","author":[{"given":"Frauke","family":"Naumann-Winter","sequence":"first","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices (BfArM); Kurt-Georg-Kiesinger-Allee 3 Bonn Germany 53175"},{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Greb","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bohlius","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Finkenhubelweg 11 Bern Switzerland 3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"},{"name":"University Hospital of Cologne; Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schnell","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"},{"name":"University Hospital of Cologne; Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"issue":"17","key":"10.1002\/14651858.CD004626.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0002|cit2","unstructured":"Giralt S MD Anderson Study Center A Randomized Phase II Trial of tandem transplantation vs thalidomide\/dexamethasone maintenance therapy for patients with multiple myeloma failing to achieve complete remission after intensive induction therapy http:\/\/utm-ext01a.mdacc.tmc.edu\/dept\/prot\/clinicaltrialswp.nsf\/Index\/DM00-196"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Wilson RL Gray ML Giralt S Barriers to second transplant for multiple myeloma in a randomised autologous tandem trial Biology of Blood and Marrow Transplantation 2003","DOI":"10.1016\/S1083-8791(03)80184-2"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0005|cit4","unstructured":"Einsele H Stem Cell Transplantation for MM: Analysis of Prognostic Factors[S9.3] Haematologica 2007 49 http:\/\/myeloma.org\/pdfs\/Kos2007_Einsele.pdf [accessed 22.2.2011]"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0004|cit5","unstructured":"Einsele H Liebisch P Bargou R Meisner C Metzner B Wandt H Single high-dose chemoradiotherapy versus tandem high-dose melphalan followed by autologous stem cell transplantation: preliminary analysis Haematologica 2005 131"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0007|cit6","unstructured":"Knop S New approaches in first-line therapy - international perspective: 3. Germany - Younger patients http:\/\/mds-forum.onkodin.de\/myelom2008\/content\/e54\/e4466\/e2568\/index_ger.html [accessed 22.2.2011]"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0006|cit7","unstructured":"Knop S Bauer K Hebart H Wandt H Tr\u00fcmper L Liebisch P A Randomized Comparison of Total-Marrow Irradiation, Busulfan and Cyclophosphamide with Tandem High-Dose Melphalan in Patients with Multiple Myeloma [#728] Blood 2007 http:\/\/myeloma.org\/ArticlePage.action?articleId=2252 [accessed 22.2.2011]"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0008|cit8","unstructured":"Goldschmidt H Single vs double HDT in multiple myeloma http:\/\/myeloma.org\/pdfs\/Kos2007_Goldschmidt.pdf [accessed 22.2.2011]"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0009|cit9","unstructured":"Goldschmidt H Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial[PL8.02] Haematologica 2005 38 http:\/\/myeloma.org\/pdfs\/Sydney2005_Goldschmidt_P8.pdf [accessed 22.2.2011]"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0010|cit10","unstructured":"Goldschmidt H Neues aus den Studiengruppen - GMMG (German-Speaking Myeloma Multicenter Group) http:\/\/mds-forum.onkodin.de\/myelom2009\/content\/e54\/e8241\/e8264\/index_ger.html [accessed 22.2.2011]"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0011|cit11","unstructured":"Goldschmidt H Single vs tandem autologous transplantation in multiple myeloma: the GMMG experience Haematologica 2003 S61"},{"issue":"26","key":"10.1002\/14651858.CD004626.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004626.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0014|cit14","unstructured":"Fermand J Alberti C Marolleau J High does therapy supported with autologous blood stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group [PL 8.05] Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD004626.pub3-BIB0015|cit15","first-page":"815a","article-title":"American Society of Hematology, Orlando 2001","volume":"98 Suppl","author":"Fermand","year":"2001","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0016|cit16","unstructured":"Mahendra P A randomised study of double versus single high dose therapy with autologous stem cell transplantation in newly diagnosed patients with Stage II\/III multiple myeloma (N0265041749] http:\/\/www.nihr.ac.uk\/Profiles\/NRR.aspx?Publication_ID=N0265041749"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.2004.06.144","article-title":"Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study","volume":"22","author":"Morris","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000253027","article-title":"Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry","volume":"122","author":"Kim","year":"2009","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0019|cit19","first-page":"207","article-title":"Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre","volume":"111","author":"Koren","year":"2010","journal-title":"Prague Medical Report"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.2003.04067.x","article-title":"Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos\/Trasplante Autologo de Medula Osea phase II trial","volume":"120","author":"Lahuerta","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Bjorkstrand B Klausen TW Remes K Gruber A Knudsen LM Bergmann OJ Double versus single high-dose melphalan 200 mg\/m\u00b2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area Hematology Reviews 2009 e2","DOI":"10.4081\/hr.2009.e2"},{"issue":"7","key":"10.1002\/14651858.CD004626.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.11168","article-title":"Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial","volume":"92","author":"Sonneveld","year":"2007","journal-title":"Haematologica"},{"issue":"18","key":"10.1002\/14651858.CD004626.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2009.26.4465","article-title":"Reiterative survival analyses of Total Therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms","volume":"28","author":"Barlogie","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004626.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Barlogie B Shaughnessy J Anaissie E van Rhee F Alsayed Y Waheed S Modeling for Cure:Total Therapy Trials for Newly Diagnosed Multiple Myeloma: Let the Math Speak! http:\/\/myeloma.uams.edu\/Modeling-for-Cure-ASH-2009.pdf [accessed 01.03.2011]","DOI":"10.1182\/blood.V114.22.744.744"},{"issue":"7","key":"10.1002\/14651858.CD004626.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","article-title":"Long-term outcome results of the first tandem autotransplant trial for multiple myeloma","volume":"135","author":"Barlogie","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD004626.pub3-BIB0029|cit29","first-page":"469","article-title":"Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma","volume":"6","author":"Barlogie","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0030|cit30","unstructured":"Horowitz Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702; NCT01109004) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01109004?term=NCT01109004&rank=1"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","article-title":"Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial","volume":"111","author":"Abdelkefi","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD004626.pub3-BIB0032|cit32","first-page":"6265","article-title":"Retraction of Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, et al. Blood 2008 Feb 15;111(4):1805-10; PM","volume":"113","author":"Abdelkefi","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"120 Suppl 12","author":"Alexander","year":"2007","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/asheducation-2007.1.311","article-title":"Stem cell transplantation in multiple myeloma","author":"Attal","year":"2007","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.seminhematol.2009.02.006","article-title":"The role of high-dose therapy with autologous stem cell support in the era of novel agents","volume":"46","author":"Attal","year":"2009","journal-title":"Seminars in Hematology"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0038|cit38","first-page":"38","article-title":"High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma","volume":"7","author":"Awedan","year":"2002","journal-title":"Annals of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD004626.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD004626.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0042|cit42","unstructured":"Barlogie B van Rhee F Anaissie E Epstein J Crowley J Shaughnessy J Should autologous transplant be part of the primary treatment in MM? Haematologica 2007 67"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Barlogie B Shaughnessy J Anaissie E van Rhee F Alsayed Y Waheed S Modeling for Cure:Total Therapy Trials for Newly Diagnosed Multiple Myeloma: Let the Math Speak! American Society of Hematology - Annual meeting held in New Orleans December 5-8, 2009","DOI":"10.1182\/blood.V114.22.744.744"},{"issue":"5","key":"10.1002\/14651858.CD004626.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD004626.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jclinepi.2004.06.003","article-title":"Gold is not always good enough: the shortcomings of randomization when evaluating interventions in small heterogeneous samples","volume":"57","author":"Blair","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD004626.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/cncr.23299","article-title":"Symptom burden after autologous stem cell transplantation for multiple myeloma","volume":"112","author":"Campagnaro","year":"2008","journal-title":"Cancer"},{"issue":"9758","key":"10.1002\/14651858.CD004626.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"9683","key":"10.1002\/14651858.CD004626.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0049|cit49","unstructured":"CHMP\/EWP\/27994\/08 Appendix 1 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man - Methodological Considerations for Using Progression-Free Survival (PFS) as Primary endpoints in confirmatory trials for registration http:\/\/www.ema.europa.eu\/pdfs\/human\/ewp\/2799408en.pdf"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.pmed.0010035","article-title":"Doing new research? Don't forget the old","volume":"1","author":"Clarke","year":"2004","journal-title":"PLoS Medicine"},{"issue":"17","key":"10.1002\/14651858.CD004626.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0052|cit52","unstructured":"CPMP\/EWP\/205\/95 Rev.3 Evaluation of Anticancer Medicinal Products in Man http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/12\/WC500017748.pdf"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1634\/theoncologist.2008-0174","article-title":"One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis?","volume":"13","author":"Curt","year":"2008","journal-title":"Oncologist"},{"issue":"6964","key":"10.1002\/14651858.CD004626.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews.","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0037-1963(01)90087-3","article-title":"The epidemiology of multiple myeloma","volume":"38 Suppl 3","author":"Durie","year":"2001","journal-title":"Seminars in Hematology"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJMe0805176","article-title":"Treatment of myeloma--are we making progress?","volume":"359","author":"Durie","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0305-7372(10)70008-6","article-title":"Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival","volume":"36 Suppl 2","author":"Durie","year":"2010","journal-title":"Cancer Treatment Reviews"},{"issue":"6","key":"10.1002\/14651858.CD004626.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7861\/clinmedicine.1-6-478","article-title":"Uses and abuses of meta-analysis","volume":"1","author":"Egger","year":"2001","journal-title":"Clinical Medicine"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0061|cit61","unstructured":"Einsele H Stem Cell Transplantation for MM: Analysis of Prognostic Factors[S9.3] Haematologica XIth International Myeloma Foundation Workshop, Kos 49"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0062|cit62","unstructured":"Effficacy working party of the European Medical Agencies Appendix 2 to the Guideline on the evaluation of Anticancer Medicinal Products in Man (CPMP\/EWP\/205\/95 Rev. 3) on Confirmatory studies in Haematological http:\/\/www.ema.europa.eu\/pdfs\/human\/ewp\/52008808enfin.pdf"},{"issue":"1","key":"10.1002\/14651858.CD004626.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0895-4356(94)00110-C","article-title":"Meta-analysis: statistical alchemy for the 21st century","volume":"48","author":"Feinstein","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0064|cit64","unstructured":"Fermand JP Should autologous transplant be part of the primary treatment in MM? Haematologica 2007 68-9 http:\/\/myeloma.org\/pdfs\/Kos2007_Fermand.pdf [accessed 22.2.2011]"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/1535-7163.MCT-06-0620","article-title":"Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach","volume":"6","author":"Fonseca","year":"2007","journal-title":"Molecular Cancer Therapy"},{"issue":"12","key":"10.1002\/14651858.CD004626.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/10428190601059753","article-title":"Relevant prognostic features of multiple myeloma and the new International Staging System","volume":"48","author":"Gertz","year":"2007","journal-title":"Leukemia & Lymphoma"},{"issue":"10","key":"10.1002\/14651858.CD004626.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clinical Proceedings"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0069|cit69","unstructured":"Gertz M Is autologous stem cell transplantation the therapy of choice for the treatment of Multiple Myeloma patients? CONTRA 2nd Heidelberg Myeloma Workshop"},{"issue":"13","key":"10.1002\/14651858.CD004626.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnci\/djp126","article-title":"Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Giralt","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nrclinonc.2010.104","article-title":"200 mg\/m(2) melphalan--the gold standard for multiple myeloma","volume":"7","author":"Giralt","year":"2010","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0072|cit72","unstructured":"Goldschmidt 2009 The GMMG-HD5 trial: bortezomib-based induction prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide-based consolidation and maintenance therapy in patients with multiple myeloma http:\/\/www.controlled-trials.com\/ISRCTN05745813 [accessed 26 May 2011] 2009"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminhematol.2007.09.001","article-title":"Activity survey and historical perspective of autologous stem cell transplantation in Europe","volume":"44","author":"Gratwohl","year":"2007","journal-title":"Seminars in Hematology"},{"issue":"15","key":"10.1002\/14651858.CD004626.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"Journal Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004626.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/bbmt.2003.50002","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review","volume":"9","author":"Hahn","year":"2003","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD004626.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.V79.11.2827.bloodjournal79112827","article-title":"Double-intensive therapy in high-risk multiple myeloma","volume":"79","author":"Harousseau","year":"1992","journal-title":"Blood"},{"issue":"15","key":"10.1002\/14651858.CD004626.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1002\/14651858.CD004626.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"360","author":"Harousseau","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0079|cit79","unstructured":"Cochrane Handbook Cochrane Handbook for Systematic Reviews of Interventions [version 5.1.0.] The Cochrane Collaboration, 2011"},{"issue":"1","key":"10.1002\/14651858.CD004626.pub3-BIB0080|cit80","first-page":"MR000006","article-title":"Publication bias in clinical trials due to statistical significance or direction of trial results","author":"Hopewell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Hopewell S Dutton S Yu L-M Chan A-W Altman DG The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed BMJ 2010","DOI":"10.1136\/bmj.c723"},{"issue":"5","key":"10.1002\/14651858.CD004626.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working group","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0083|cit83","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (editor) Stem cell transplantation in multiple myeloma https:\/\/www.iqwig.de\/download\/N05-03C_Vorbericht_Stammzelltransplantation_bei_Multiplem_Myelom.pdf 2011"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2006.00685.x","article-title":"Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003","volume":"77","author":"Jantunen","year":"2006","journal-title":"European Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.2005.00605.x","article-title":"Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients","volume":"76","author":"Jantunen","year":"2006","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3816\/CLML.2010.n.060","article-title":"Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group","volume":"10","author":"Johnsen","year":"2010","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"5","key":"10.1002\/14651858.CD004626.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cncr.23281","article-title":"In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample","volume":"112","author":"Jones","year":"2008","journal-title":"Cancer"},{"issue":"7303","key":"10.1002\/14651858.CD004626.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD004626.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1553-2712.2008.00193.x","article-title":"From the emergency department to vital statistics: cause of death uncertain","volume":"15","author":"Keirns","year":"2008","journal-title":"Academic Emergency Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004626.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jclinepi.2006.11.008","article-title":"Readers should systematically assess methods used to identify, measure and analyze confounding in observational cohort studies","volume":"60","author":"Klein-Geltink","year":"2007","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD004626.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jclinepi.2004.03.011","article-title":"Methods to assess intended effects of drug treatment in observational studies are reviewed","volume":"57","author":"Klungel","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Koreth","year":"2007","journal-title":"Biololgy of Blood and Marrow Transplantation"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0093|cit93","unstructured":"Kort\u00fcm M Einsele H Naumann R Peest D Liebisch P Goldschmidt H Leitlinie Multiples Myelom http:\/\/www.dgho.de\/onkopedia\/Multiples%20Myelom [accessed 26.05.11] 2010"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.290.4.495","article-title":"Factors associated with failure to publish large randomized trials presented at an oncology meeting","volume":"290","author":"Krzyzanowska","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD004626.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Kumar A Djulbegovic B Author reply to Giralt et al and Tricot et al: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis Journal of the National Cancer Institute 2009 966 7","DOI":"10.1093\/jnci\/djp128"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Kumar A Djulbegovic B Author reply to Mehta: Re: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis Journal of the National Cancer Institute 2009 1431 3","DOI":"10.1093\/jnci\/djp321"},{"issue":"7167","key":"10.1002\/14651858.CD004626.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.317.7167.1185","article-title":"The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials","volume":"317","author":"Kunz","year":"1998","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD004626.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD004626.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2005-07-2610","article-title":"Role of VAD in the initial treatment of multiple myeloma","volume":"106","author":"Lane","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-070209-175325","article-title":"Multiple myeloma","volume":"62","author":"Laubach","year":"2011","journal-title":"Annual Review of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.md.0000173272.71949.a1","article-title":"A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy","volume":"84","author":"Levy","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/asheducation-2008.1.142","article-title":"Old and new cancers after hematopoietic-cell transplantation","author":"Majhail","year":"2008","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"20","key":"10.1002\/14651858.CD004626.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jnci\/djp320","article-title":"Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Mehta","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"issue":"15","key":"10.1002\/14651858.CD004626.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD004626.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":"Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD004626.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.2004.06.144","article-title":"Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study","volume":"22","author":"Morris","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/asheducation-2008.1.297","article-title":"Plasma cell disorders: an historical perspective","author":"Munshi","year":"2008","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"18","key":"10.1002\/14651858.CD004626.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD004626.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004626.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2796.2010.02324.x","article-title":"Clinical impact of chromosomal aberrations in multiple myeloma","volume":"269","author":"Nahi","year":"2011","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0116|cit116","unstructured":"NCCN Multiple Myeloma Panel Multiple Myeloma, Version 3.2010 NCCN Clinical pratice guidelines in Oncology 2011"},{"issue":"8","key":"10.1002\/14651858.CD004626.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(01)00453-3","article-title":"Meta-analyses of randomised clinical trials in oncology","volume":"2","author":"Pignon","year":"2001","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004626.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1002\/14651858.CD004626.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/83.10.1142","article-title":"Treatment of myeloma: cure vs control","volume":"83","author":"Rajkumar","year":"2008","journal-title":"Mayo Clinical Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1634\/theoncologist.2008-0133","article-title":"Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology","volume":"13","author":"Ramsey","year":"2008","journal-title":"Oncologist"},{"issue":"9308","key":"10.1002\/14651858.CD004626.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(02)07882-0","article-title":"Sample size slippages in randomised trials: exclusions and the lost and wayward","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"10.1002\/14651858.CD004626.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2007.14.6795","article-title":"Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications","volume":"26","author":"Tam","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD004626.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2008-06-163782","article-title":"Is more better in myeloma?","volume":"112","author":"Tricot","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1002\/14651858.CD004626.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnci\/djp127","article-title":"Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Tricot","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1002\/14651858.CD004626.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD004626.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1371\/journal.pmed.0050067","article-title":"Observational research, randomised trials, and two views of medical science","volume":"5","author":"Vandenbroucke","year":"2008","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004626.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"Elm","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"34","key":"10.1002\/14651858.CD004626.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2006.08.3048","article-title":"Problems with up-front randomization in clinical trials","volume":"24","author":"Wheatley","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004626.pub3-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Wilson RL Gray ML Giralt S Barriers to second transplant for multiple myeloma in a randomised autologous tandem trial Biology of Blood and Marrow Transplantation IBMTR\/ABMTR Participants' meeting, Keystone Colorado, January 2003. 2003","DOI":"10.1016\/S1083-8791(03)80184-2"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004626.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:17:28Z","timestamp":1729617448000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004626.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":129,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004626.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,17]]}}}